Total Funding
16
Total FundingGrant raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
NatiMab Therapeutics identifies and develops human antibodies (Abs) for the therapy and diagnosis of infectious diseases and cancer.
Maurizio Denaro: Head of Development and Founder- Marianne Murphy: Head of Discovery and Co-Founder
About the Company
NatiMab Therapeutics identifies and develops human antibodies (Abs) for the therapy and diagnosis of infectious diseases and cancer.
NatiMab Therapeutics is an Italian SME located in the premises of the Bioindustry Park Canavese scientific and technological park, at Colleretto Giacosa (Torino). Registered on 02/01/2008 in Torino, NatiMab
was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens. On 10/12/2014, two previously key collaborators, Francesco Novelli and Guido Forni joined the company as shareholders.
Women Founded
